Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors
US7098330B2 · kind B2 · utility
83Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2001 |
| Grant date | Aug 29, 2006 |
| Priority date | — |
| Expiry date | Mar 27, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention describes novel pyrazole compounds of formula III:wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5–8 membered carbocyclo ring; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.